Episode Details

Medpace Holdings (MEDP) Q2 2026 — Medpace Holdings (MEDP), the elite full-service contract research organization (CRO) that runs clinical trials for biotech and pharma, reported a strong Q2 2026: GAAP diluted EPS of $4.25 beat the ~$3.98 estimate on revenue of $707.3M (+17.2% YoY, from $603.3M). For a CRO the whole story is bookings — and net new business awards jumped 28% to $795.7M, a 1.13x book-to-bill, while EBITDA rose ~18% to $153.4M. Management RAISED full-year guidance to revenue of $2.81B-$2.89B and GAAP EPS of $17.25-$17.95. The stock popped ~17% on the print to ~$528 (still ~16% below its $629 high). The catch: after that pop, our owner-earnings DCF pegs fair value near $540 — essentially at the price — and the demand base (mid-size biotech funding) is cyclical, with backlog up just 4.9% versus revenue up 17%. Our call: HOLD. Medpace is one of the best businesses in healthcare that most investors have never heard of — the elite, founder-led CRO that biotech and pharma hire to design and run their clinical trials. Q2 2026 was a statement quarter: GAAP EPS of $4.25 beat ~$3.98, revenue grew 17.2% to $707.3M, EBITDA rose ~18% to $153.4M, and — the number that matters most for a CRO — net new business awards jumped 28% to $795.7M (a 1.13x book-to-bill). Management RAISED full-year guidance (revenue $2.81-2.89B, EPS $17.25-17.95), and the stock popped ~17% on the print to ~$528. After a scary stretch where biotech funding froze and the stock was nearly halved from $629 to $373, growth is clearly back. So the question isn't quality — it's price. We value Medpace on an owner-earnings DCF (normalized FCF ~$580M/yr, net cash, ~28.5M shares) across two paths: a cyclical case (+9%->4%) worth ~$408-574 and a reacceleration case (+14%->5%) worth ~$535-785. Cyclical-weighted, our central fair value lands near $540 — essentially on top of the $528 price. Three honest tells keep us cautious: backlog grew only 4.9% while revenue grew 17% (coverage is thinning, so book-to-bill must stay above 1); the company slowed its own buyback sharply (~$295M in Q2 versus $913M in 1H 2025) as the stock recovered; and part of the cash flow is flattered by customer advances. The whole thesis rests on something Medpace doesn't control: whether biotech funding stays open. Our call: HOLD, 3/5 — an elite operator with real momentum, but no margin of safety after the pop. We actually AGREE with Wall Street here (consensus Hold, ~$503 average target that already sits below the price). Own the quality; add on weakness toward the mid-$400s. Watch bookings and book-to-bill every quarter. Not financial advice. THE CALL: HOLD (3/5, AN ELITE CRO WHOSE GROWTH ROARED BACK — BUT FAIRLY PRICED AFTER A 17% POP, WITH NO MARGIN OF SAFETY) — base-case value ~$540 vs ~$528 today. What to watch: hard evidence the biotech-funding recovery is durable — two or three more quarters of book-to-bill above 1.1x, awards still climbing, and backlog finally growing in line with revenue — which would validate the reacceleration path (~$637 at 9%) and justify paying up; the risk to respect is the opposite, a biotech funding freeze that stalls net new awards and lifts cancellations, which at ~30x forward earnings could re-rate the stock hard Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.